KYV-101

Kyverna reports first use of KYV-101 for multiple sclerosis treatment
Clinical Trials Arena
Tue, 04/2/24 - 11:27 am
Kyverna Therapeutics
KYV-101
multiple sclerosis
FDA clears Kyverna’s IND for scleroderma therapy
Pharmaceutical Business Review
Thu, 10/12/23 - 10:06 am
Kyverna Therapeutics
KYV-101
scleroderma
FDA
Kyverna Files First IND to Leverage CAR-T Therapy for Lupus
BioSpace
Thu, 10/20/22 - 10:32 am
Kyverna Therapeutics
KYV-101
CAR-T
lupus nephritis